Tarlatamab Administration and Postinfusion Monitoring

EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis

EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC

EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management

EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC

EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration

EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation

EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

Now Viewing

EP: 8.Tarlatamab Administration and Postinfusion Monitoring

EP: 9.Essential Patient and Caregiver Education for Tarlatamab Treatment Success

EP: 10.Neurological Toxicity Recognition: ICANS Assessment and Management

EP: 11.CRS Recognition and Intervention: Timing and Clinical Features

EP: 12.Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue

EP: 13.Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

EP: 14.Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS

EP: 15.Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management

EP: 16.Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum

EP: 17.Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit

Summary for Physicians:

Tarlatamab Administration:

• Route: Intravenous (IV) infusion
• Initial dosing: Start with lower doses to monitor for adverse effects, gradually increasing as tolerated.
• Infusion schedule: IMDELLTRA is administered as a 1-hour IV infusion every two weeks (Q2W) following an initial step-up dosing schedule. Patients should be monitored for 22–24 hours from the start of the infusion in an appropriate healthcare setting.

Monitoring Protocol Post Infusion:

• Immediate monitoring:
• Patients are observed for 1 to 2 hours post infusion to monitor for acute reactions such as cytokine release syndrome (CRS).

• Monitoring includes vital signs, oxygen saturation, and symptoms of infusion-related reactions.
• Ongoing monitoring:
• Regular follow-up visits (usually 24-48 hours post infusion) to assess for delayed adverse effects.

• Patients are educated on self-monitoring for symptoms such as fever, chills, or shortness of breath.

• Continuous assessment for immune-related toxicities.

Challenges:

Ensuring timely detection of CRS or other adverse events and having adequate support for emergency interventions.